MA49617A - Analogues d'egf(a), préparation, formulations et utilisations associées - Google Patents

Analogues d'egf(a), préparation, formulations et utilisations associées

Info

Publication number
MA49617A
MA49617A MA049617A MA49617A MA49617A MA 49617 A MA49617 A MA 49617A MA 049617 A MA049617 A MA 049617A MA 49617 A MA49617 A MA 49617A MA 49617 A MA49617 A MA 49617A
Authority
MA
Morocco
Prior art keywords
egf
analogues
formulations
preparation
related uses
Prior art date
Application number
MA049617A
Other languages
English (en)
Inventor
Kim Vilbour Andersen
Florian Dismer
Jesper F Lau
Bhavesh Premdjee
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49617A publication Critical patent/MA49617A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA049617A 2017-07-19 2018-07-19 Analogues d'egf(a), préparation, formulations et utilisations associées MA49617A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17182011 2017-07-19

Publications (1)

Publication Number Publication Date
MA49617A true MA49617A (fr) 2020-05-27

Family

ID=59383424

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049617A MA49617A (fr) 2017-07-19 2018-07-19 Analogues d'egf(a), préparation, formulations et utilisations associées

Country Status (6)

Country Link
US (1) US20200165313A1 (fr)
EP (1) EP3655426A1 (fr)
JP (1) JP2020527159A (fr)
CN (1) CN111164098A (fr)
MA (1) MA49617A (fr)
WO (1) WO2019016300A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
AR112760A1 (es) 2017-07-19 2019-12-11 Novo Nordisk As Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)
BR112022000529A2 (pt) 2019-08-07 2022-03-03 Novo Nordisk As Composição farmacêutica
AR133774A1 (es) 2023-09-11 2025-10-29 Novo Nordisk As Anticuerpos de dominio anti-il-6

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2363123C (fr) 1999-02-22 2011-09-06 Kenneth Iain Cumming Dose orale solide contenant un agent de potentialisation
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
MY195199A (en) * 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents

Also Published As

Publication number Publication date
CN111164098A (zh) 2020-05-15
US20200165313A1 (en) 2020-05-28
WO2019016300A1 (fr) 2019-01-24
JP2020527159A (ja) 2020-09-03
EP3655426A1 (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
IL288423A (en) Cannabinoid formulations
EP3732185A4 (fr) Conjugués et préparation et utilisation associées
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA51287A (fr) Analogues d'incrétine et leurs utilisations
SG10201808151RA (en) Cortistatin analogues and syntheses and uses thereof
EP3359241A4 (fr) Formulations d'analogues de pthrp, timbres transdermiques de celles-ci, et utilisations de celles-ci
IL288111A (en) Imatinib formulations, their production and uses
MA54244A (fr) Vecteurs végétaux, compositions et utilisations associées
SI3927315T1 (sl) Okusne formulacije
LT3348317T (lt) Žaislas, paeiliui atskleidžiantis vaikui staigmenas
SG11202102383VA (en) Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3347006A4 (fr) Analogues deutérés d'étifoxine, leurs dérivés et leurs utilisations
EP3411121A4 (fr) Conjugués glucose de triptolide, analogues et utilisations correspondants
EP4058568A4 (fr) Vecteurs végétaux, compositions et utilisations associées
EP3436434A4 (fr) Analogues d'indoline et leurs utilisations
EP3980009A4 (fr) Formulations à libération modifiée et utilisations associées
MX372702B (es) Una composicion antimicrobiana.
EP3723836A4 (fr) Dispositif d'administration intranasale
IN2014KO00357A (fr)
IL269305A (en) Cannabinoid formulations and dosage
EP3401685A4 (fr) Agent diagnostique et médicament comprenant adamts13 comme ingrédient principal
DK3911298T3 (da) Formuleringer
PH12018501758A1 (en) Oritavancin formulations
EP3634507C0 (fr) Plates-formes d'administration de médicament prolongée par voie orale